Every Form 4 that Encompass Health Corporation (EHC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EHC filings page.
Encompass Health Corp director Greg D. Carmichael acquired 28 restricted stock units on October 15, 2026. The award was credited under outstanding award agreements in connection with common-stock dividend payments. His reported direct holdings following the transaction were 20,377 shares. Encompass Health paid a $0.21-per-share dividend; the closing price on the payment date was $127.77.
Encompass Health Corp director Terrance Williams acquired 28 restricted stock units on October 15, 2026, under outstanding RSU award agreements. The units were credited in connection with a common-stock dividend of $0.21 per share; the closing price on the dividend payment date was $127.77. His reported direct holdings following the transaction were 16,887 shares.
Encompass Health Corp director Nancy M. Schlichting acquired an award of 38 restricted stock units (RSUs) on October 15, 2026, in connection with a common-stock dividend payment. Her reported direct holdings after the transaction were 23,010 shares. The dividend was $0.21 per share, and the closing price on the payment date was $127.77.
Encompass Health Corp (EHC) director Joan E. Herman acquired 81 restricted stock units on October 15, 2026, under outstanding award agreements that credit additional RSUs in connection with common stock dividends. Encompass Health paid a $0.21 per-share dividend that day, when the closing price was $127.77. Her reported direct holdings following the award were 49,724 shares.
Encompass Health Corp director Edward M. Christie III reported acquiring 221 common shares on October 19, 2026, at a weighted average price of $126.63 per share through the Directors Deferred Stock Investment Plan, using quarterly fee deferrals and the October 15 dividend. He also received 11 additional RSUs on October 15 under existing award agreements in connection with the $0.21-per-share dividend.
Encompass Health Corp director Christopher R. Reidy acquired 284 common shares on October 19, 2026, at a weighted average price of $126.89 per share. The shares were purchased through the Directors Deferred Stock Investment Plan using quarterly fee deferrals and the $0.21-per-share dividend paid October 15; purchase prices ranged from $126.83 to $126.89. On October 15, Reidy also received an award of 20 restricted stock units credited in connection with the dividend.
Encompass Health director Cain A. Hayes acquired an award of 4 restricted stock units (RSUs) on October 15, 2026, associated with a common-stock dividend. Hayes's reported direct holdings after the award were 2,100 shares. Encompass Health paid a $0.21 per-share dividend that day, when the closing price was $127.77.
Encompass Health Corp director Kevin J. O'Connor acquired 18 restricted stock units on October 15, 2026, as a dividend-related award under outstanding award agreements. The company paid a common-stock dividend of $0.21 per share that day, when the closing price was $127.77. O'Connor's reported direct holdings following the transaction were 11,600 shares.
Encompass Health Corp director Leslye G. Katz received an award of 81 restricted stock units (RSUs) on October 15, 2026, under outstanding award agreements that credit RSUs in connection with common-stock dividends. Encompass Health paid a $0.21-per-share dividend that day, and the closing price was $127.77. Her reported direct holdings following the award were 49,724 shares.
Encompass Health Corp (EHC) reported that Chief Accounting Officer Andrew L. Price sold Encompass Health Common Stock in a non-derivative transaction. On 2026-08-31, he sold 5,211 shares at $120.93 per share in an open market or private transaction. Following this sale, he directly holds 69,483 shares of Encompass Health Common Stock. The filing does not indicate that the transaction was made under a Rule 10b5-1 trading plan.
For Encompass Health Corp (EHC), EVP, General Counsel & Secretary John Patrick Darby exercised 4,858 non-qualified stock options on 2026-08-31 at an exercise price of $35.06 per share, acquiring an equal number of Encompass Health common shares, and on the same date sold 4,858 shares at $121.09 per share. The option exercise price and option share amount were adjusted under the company’s 2016 Omnibus Performance Incentive Plan to reflect the spin-off distribution of Enhabit, Inc. The filing’s Rule 10b5-1 checkbox was not marked as being pursuant to a trading plan.
Encompass Health Corp executive Douglas E. Coltharp, EVP & Chief Financial Officer, reported selling 18,869 shares of Encompass Health common stock on 2026-08-10 in a sale classified as an open market or private transaction at a weighted average price of $125.38 per share, with individual prices ranging from $125.03 to $125.69. Following this transaction, he directly holds 50,508 shares and also reports indirect holdings through irrevocable trusts and a spouse.
Encompass Health Corp President & CEO Mark J. Tarr reported two open-market sales of Encompass Health common stock on 2026-08-10. He sold 171,569 shares at a weighted average price of $125.46 and 1,579 shares at a weighted average price of $126.06, with each sale executed in multiple transactions within specified price ranges described in the footnotes. Post-transaction share holdings are not reported in this filing.
Encompass Health Corp executive John Patrick Darby, EVP, General Counsel & Secretary, reported selling 8,906 shares of Encompass Health common stock on 2026-08-10 in an open-market or private transaction. The weighted average sale price was $125.95 per share, across multiple trades between $125.94 and $126.04, leaving him with 75,041 shares held directly after the sale.
Encompass Health director Christopher R. Reidy acquired equity through routine compensation-related awards. On July 16, 2026 he received 319 restricted stock units tied to a $0.19 dividend and a $109.88 closing price, and on July 15, 2026 he acquired 21 shares via the Directors Deferred Stock Investment Plan, bringing his direct holdings to 17,777 common shares.
Encompass Health Corp director Edward M. Christie III acquired 248 shares of Encompass Health common stock on July 16, 2026 at a weighted average price of $112.43 per share, plus 11 additional shares on July 15, 2026 from dividend-related awards and director fee deferrals, for a total of 259 shares and direct holdings of 9,345 shares.
Williams Terrance reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Terrance Williams received an automatic grant of 29 restricted stock units (RSUs) on July 15, 2026. The RSUs were credited as a dividend equivalent on existing awards, tied to a $0.19 per share common dividend and a $109.88 closing stock price, increasing his direct holdings to 16,859 shares.
SCHLICHTING NANCY M reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Nancy M. Schlichting received an automatic award of 40 restricted stock units tied to Encompass Health common stock on July 15, 2026. The award represents dividend equivalents on existing RSUs, based on a $0.19 per-share dividend and a $109.88 closing price. Following this award, her directly reported holdings total 22,972 shares.
Encompass Health Corp director Kevin J. O'Connor reported an automatic grant/award acquisition of 19 Encompass Health Common Stock-equivalent RSUs on July 15, 2026, at $0.00 per share. These RSUs were credited under existing restricted stock unit agreements in connection with a $0.19 per-share dividend, when the stock closed at $109.88. Following this award, O'Connor directly holds 11,582 shares.
Encompass Health Corp reported that non-employee director Leslye G. Katz acquired 85 Encompass Health Common Stock-equivalent RSUs at $0.00 per unit under a grant/award transaction. These RSUs were credited as dividend equivalents tied to a $0.19 per share common stock dividend, using a $109.88 closing price on July 15, 2026. Following this award, Katz’s direct holdings total 49,643 shares/units.
Encompass Health Corp director Joan E. Herman reported an automatic acquisition of 85 shares of common stock in the form of restricted stock units (RSUs). These RSUs were credited under outstanding award agreements in connection with the July 15, 2026 common stock dividend of $0.19 per share, when the stock’s closing price was $109.88. Following this dividend-equivalent RSU award, Herman directly holds 49,643 shares of Encompass Health common stock.
Hayes Cain A reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp reports that director Cain A. Hayes received a grant of 4 units of Encompass Health Common Stock on July 15, 2026. According to the award terms, these restricted stock units were credited as dividend equivalents following a $0.19 per-share dividend when the stock closed at $109.88. After this award, Hayes holds a total of 2,096 shares directly, reflecting routine, compensation-related accrual rather than an open-market purchase or sale.
CARMICHAEL GREG D reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Greg D. Carmichael received an automatic award of 29 restricted stock units (RSUs) tied to a common stock dividend paid on July 15, 2026. These RSUs were credited at a dividend of $0.19 per share and a closing price of $109.88, bringing his reported direct Encompass Health equity holdings to 20,349 units.
Encompass Health Corp EVP & CFO Douglas Coltharp reported a combination of option exercise and share sales in Encompass Health Common Stock. He exercised 27,694 shares from a non-qualified stock option at an exercise price of $32.94 per share and acquired the same number of common shares.
On the same date, he sold a total of 27,694 shares of common stock in open-market transactions at weighted average prices of about $106.83 and $107.28 per share, leaving 69,377 directly held shares. The option grant, originally exercisable until October 28, 2026, now has 0 options remaining after this exercise.
Indirect holdings reported after these transactions include 37,749 shares held by his spouse, 125,631 shares held by an irrevocable trust for the benefit of children, and 27,480 shares held by another irrevocable trust. A footnote states the option terms were adjusted under the 2016 Omnibus Performance Incentive Plan for the spin-off distribution of Enhabit, Inc.
Encompass Health Corp executive Patrick William Tuer, EVP and Chief Operating Officer, reported an open-market sale of Encompass Health Common Stock. He sold 682 shares at a price of $104.56 per share on May 11, 2026, and held 24,755 shares directly after this transaction.
O'Connor Kevin J. reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Kevin J. O'Connor received a grant of 1,634 shares of Encompass Health Common Stock. The shares were awarded at no cash cost as part of his annual restricted stock unit grant under the Corporation's 2025 Omnibus Performance Incentive Plan. Following this equity award, O'Connor directly holds 11,563 shares of Encompass Health Common Stock, reflecting a routine compensation-related increase in his ownership stake.
Christie Edward M III reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp reported that director Edward M. Christie III received an annual equity award in the form of 1,634 shares of Encompass Health Common Stock on May 7, 2026. The shares were granted at $0.00 per share as restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan, meaning they are compensation rather than a market purchase.
After this award, Christie directly owns 9,086 shares of Encompass Health Common Stock. This is a routine director compensation grant, not an open‑market buy or sale, and it does not reflect a discretionary trading decision.
Reidy Christopher R reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Christopher R. Reidy received an equity grant of 1,634 shares of Encompass Health Common Stock. The shares were awarded at a price of $0.00 per share as part of his annual grant of restricted stock units under the corporation's 2025 Omnibus Performance Incentive Plan.
Following this grant, Reidy directly holds 17,437 shares of Encompass Health Common Stock. This transaction reflects a compensation-related award rather than an open-market purchase or sale.
Hayes Cain A reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Cain A. Hayes reported receiving an annual grant of 1,634 shares of Encompass Health Common Stock, awarded as restricted stock units under the corporation's 2025 Omnibus Performance Incentive Plan. After this compensation-related award, Hayes directly holds 2,092 shares.
CARMICHAEL GREG D reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Greg D. Carmichael received an equity award of 1,634 shares of Encompass Health Common Stock. The shares were granted on 2026-05-07 as an annual grant of restricted stock units under the Corporation's 2025 Omnibus Performance Incentive Plan. Following this grant, Carmichael directly holds 20,320 shares of Encompass Health Common Stock.
Williams Terrance reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Terrance Williams received an equity grant of 1,634 shares of Encompass Health Common Stock. The shares were awarded at no cash cost as an annual grant of restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan, bringing his direct holdings to 16,830 shares.
KATZ LESLYE G reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Leslye G. Katz received an annual grant of 1,634 shares of Encompass Health Common Stock on May 7, 2026. The award was granted at no cash cost as restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan.
Following this grant, Katz directly holds 49,558 shares of Encompass Health Common Stock. This is a routine equity compensation award rather than an open-market purchase or sale, so it does not reflect a discretionary trading decision in the company’s stock.
HERMAN JOAN E reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Joan E. Herman received a grant of 1,634 Encompass Health common shares as a compensation award. The shares were granted at no cash cost to Herman as part of an annual restricted stock unit award under the corporation's 2025 Omnibus Performance Incentive Plan. Following this grant, Herman directly holds 49,558 shares of Encompass Health common stock. This is a routine equity compensation grant rather than an open-market purchase or sale.
SCHLICHTING NANCY M reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Nancy M. Schlichting received an annual grant of 1,634 restricted stock units of Encompass Health Common Stock at no cost under the corporation's 2025 Omnibus Performance Incentive Plan. Following this grant, she directly holds 22,932 shares of Encompass Health Common Stock.
CARMICHAEL GREG D reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Greg D. Carmichael received additional stock-based compensation through a routine dividend-related award. On April 15, 2026, he was granted 27 restricted stock units (RSUs) of Encompass Health Common Stock at no cash cost, increasing his direct holdings to 18,686 shares.
The footnote explains that, under outstanding RSU award agreements, extra RSUs are credited to each non-employee director when common stock dividends are paid. The number of RSUs is based on the existing RSU balance, the per share dividend of $0.19, and the $105.24 closing price on the dividend payment date.
Encompass Health Corp director Edward M. Christie III reported acquiring additional common stock through compensation-related programs. On April 16, he received 261 shares at a weighted average price of $106.17 per share, tied to restricted stock units that accrue additional units when common stock dividends are paid.
The RSU credit was based on a $0.19 per share dividend paid on April 15 and a closing price of $105.24 on that date. He also acquired 9 shares on April 15 through the Directors Deferred Stock Investment Plan, where deferred director fees and associated dividends are used to purchase Encompass Health common stock in the market. Following these awards, he directly holds 7,452 shares of Encompass Health common stock.
Hayes Cain A reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Hayes Cain A received an automatic award of 1 restricted stock unit linked to a common stock dividend. This award arose under outstanding RSU agreements when Encompass Health paid a $0.19 per share dividend and the stock closed at $105.24 on April 15, 2026. Following this grant, Cain directly holds 458 shares or units of Encompass Health common stock.
Encompass Health Corp director Joan E. Herman received an automatic share-based award tied to a dividend payment. On April 15, 2026, she acquired 85 Encompass Health common stock equivalent restricted stock units at no cash cost, credited under existing RSU agreements in connection with a $0.19 per share dividend and a $105.24 closing price. Following this grant, she directly holds 47,924 shares of Encompass Health common stock.
Encompass Health Corp director Leslye G. Katz received an equity award tied to a dividend reinvestment feature. On April 15, 2026, she acquired 85 restricted stock units (RSUs) for Encompass Health common stock at no cost, credited in connection with a $0.19 per share dividend and a $105.24 closing price. Following this routine compensation-related award, she directly holds 47,924 shares of Encompass Health common stock.
Encompass Health Corp director Kevin J. O’Connor reported a small compensation-related equity award. On April 15, 2026, he acquired 17 Encompass Health common stock restricted stock units credited in connection with a common stock dividend. These units were valued using the $105.24 closing price on the dividend payment date. Following this award, his directly held Encompass Health common stock position stands at 9,929 shares.
Encompass Health Corp director Christopher R. Reidy increased his direct holdings through routine equity compensation events. On April 16, 2026, he acquired 334 shares of Encompass Health Common Stock at a weighted average of $106.48 per share as a grant or award. On April 15, 2026, he also acquired 19 shares at $0.00 per share through a directors’ deferred stock investment plan and dividend reinvestment tied to a $0.19 per share dividend and a $105.24 closing price. Following these transactions, he directly holds 15,803 shares of Encompass Health Common Stock.
SCHLICHTING NANCY M reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Nancy M. Schlichting received an automatic grant of 39 restricted stock units (RSUs) tied to a dividend payment. These RSUs were credited on April 15, 2026 in connection with Encompass Health’s common stock dividend of $0.19 per share.
The RSU credit was calculated based on the number of RSUs already in the director’s account, the per share dividend, and the closing stock price of $105.24 on the dividend payment date. After this award, Schlichting directly holds 21,298 shares of Encompass Health common stock. This is a routine, non-cash compensation-related accrual rather than an open-market stock purchase or sale.
Williams Terrance reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Terrance Williams received 27 restricted stock units (RSUs) as a grant tied to a dividend payment. These RSUs were credited on April 15, 2026, when the company paid a $0.19 per share dividend and the stock closed at $105.24. After this award, Williams directly holds a total of 15,196 shares/RSUs of Encompass Health common stock. The transaction reflects a compensation-related RSU credit rather than an open-market stock purchase.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported an open-market sale and a charitable gift of company stock. On March 9, 2026, he sold 11,937 shares of Encompass Health common stock at $107 per share, then donated 3,000 shares as a bona fide gift to a donor advised fund administered by Schwab. After these transactions, Fay directly holds 86,325 shares of Encompass Health common stock, indicating he retains a substantial equity stake in the company.
Encompass Health Corp Chief Accounting Officer handles tax withholding via share disposition
Encompass Health Corp executive Andrew L. Price reported a tax-withholding disposition of 307 shares of Encompass Health common stock on this Form 4. The shares, valued at $107.88 each, were withheld or surrendered to cover tax obligations from vesting restricted stock, not sold in an open‑market trade.
After this transaction, Price directly holds 74,694 shares of Encompass Health common stock.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported a small share disposition related to tax withholding. On the transaction date, 280 shares of Encompass Health common stock were withheld at $107.88 per share to cover tax obligations from vesting restricted stock. After this tax-withholding disposition, Fay directly owned 101,262 shares of Encompass Health common stock.
Encompass Health Corp Chief Medical Officer Elissa Joy Charbonneau had 369 shares of Encompass Health common stock withheld at a price of $107.88 per share to cover tax obligations from vesting restricted stock. After this tax-withholding disposition, she directly holds 17,644.061 shares.
Encompass Health Corp executive John Patrick Darby reported routine equity compensation activity. He received a grant of 5,967 non-qualified stock options at $108.06 per share, which become exercisable in equal installments over three years starting March 2, 2027. Separately, 416 shares of common stock were disposed of to satisfy tax withholding obligations tied to the vesting of related restricted stock, rather than through an open-market sale.
Encompass Health Corp President & CEO Mark J. Tarr reported a mix of equity award activity and tax-related share withholding. He received a grant of non-qualified stock options covering 35,461 shares at an exercise price of $108.06 per share. According to the disclosure, these options become exercisable in equal annual installments over a three-year period beginning March 2, 2027.
In a separate transaction, 2,187 shares of Encompass Health common stock were withheld or surrendered at $107.88 per share to satisfy tax withholding obligations tied to the vesting of related restricted stock. After these transactions, Tarr directly held 440,962 shares of common stock.
Encompass Health Corp executive Patrick William Tuer reported two equity-related transactions. He received a grant of 10,502 non-qualified stock options at an exercise price of $108.06 per share, which become exercisable in three equal annual installments starting on March 2, 2027. Separately, 545 shares of common stock at $107.88 per share were withheld to cover tax obligations arising from the vesting of related restricted stock, leaving him with 25,437 directly held shares.